Gilead's remdesivir is not recommended for patients hospitalised with Covid-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organisation ...

Antiviral remdesivir should not be used as a routine treatment for Covid-19 patients in critical care wards, the head of one of the world's top bodies representing intensive care doctors said, in a blow to the drug developed by US firm Gilead.

The European Union's executive said on Wednesday it had agreed to buy a limited supply of the Covid-19 medicine remdesivir from US drugmaker Gilead to address the short-term needs of European patients

Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill Covid-19 patients.